Free Trial

Avacta Group (AVCT) Competitors

Avacta Group logo
GBX 28 -0.25 (-0.88%)
As of 11:49 AM Eastern

AVCT vs. SLN, PRTC, OXB, FARN, HZD, VRP, ARIX, BVXP, 4BB, and CIR

Should you be buying Avacta Group stock or one of its competitors? The main competitors of Avacta Group include Silence Therapeutics (SLN), PureTech Health (PRTC), Oxford Biomedica (OXB), Faron Pharmaceuticals Oy (FARN), Horizon Discovery Group plc (HZD.L) (HZD), Verona Pharma plc (VRP.L) (VRP), Arix Bioscience (ARIX), Bioventix (BVXP), 4basebio (4BB), and Circassia Group (CIR). These companies are all part of the "biotechnology" industry.

Avacta Group vs.

Avacta Group (LON:AVCT) and Silence Therapeutics (LON:SLN) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, risk, media sentiment, earnings, community ranking, dividends, analyst recommendations, institutional ownership and valuation.

Silence Therapeutics has lower revenue, but higher earnings than Avacta Group. Avacta Group is trading at a lower price-to-earnings ratio than Silence Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Avacta Group£26.29M4.05-£30.08M-£7.77-3.60
Silence Therapeutics£11.35M0.00N/A-£48.60N/A

Avacta Group received 9 more outperform votes than Silence Therapeutics when rated by MarketBeat users. However, 68.81% of users gave Silence Therapeutics an outperform vote while only 67.30% of users gave Avacta Group an outperform vote.

CompanyUnderperformOutperform
Avacta GroupOutperform Votes
212
67.30%
Underperform Votes
103
32.70%
Silence TherapeuticsOutperform Votes
203
68.81%
Underperform Votes
92
31.19%

Silence Therapeutics has a net margin of 0.00% compared to Avacta Group's net margin of -114.45%. Silence Therapeutics' return on equity of 0.00% beat Avacta Group's return on equity.

Company Net Margins Return on Equity Return on Assets
Avacta Group-114.45% -74.00% -21.80%
Silence Therapeutics N/A N/A N/A

10.2% of Avacta Group shares are owned by institutional investors. 32.9% of Avacta Group shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Avacta Group had 1 more articles in the media than Silence Therapeutics. MarketBeat recorded 1 mentions for Avacta Group and 0 mentions for Silence Therapeutics. Avacta Group's average media sentiment score of 0.75 beat Silence Therapeutics' score of 0.00 indicating that Avacta Group is being referred to more favorably in the media.

Company Overall Sentiment
Avacta Group Positive
Silence Therapeutics Neutral

Summary

Avacta Group beats Silence Therapeutics on 8 of the 12 factors compared between the two stocks.

Get Avacta Group News Delivered to You Automatically

Sign up to receive the latest news and ratings for AVCT and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

AVCT vs. The Competition

MetricAvacta GroupBiotechnology IndustryMedical SectorLON Exchange
Market Cap£106.38M£128.48M£5.31B£2.62B
Dividend Yield3.97%3.74%5.20%5.05%
P/E Ratio-3.603.4126.69134.81
Price / Sales4.054,169.40393.58221,342.27
Price / Cash15.0013.1938.2528.03
Price / Book1.9033.216.743.84
Net Income-£30.08M-£91.56M£3.23B£5.88B
7 Day Performance-15.15%2.85%0.01%3.52%
1 Month Performance-15.15%7.44%8.69%25.34%
1 Year Performance-36.36%101.47%18.36%130.33%

Avacta Group Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
AVCT
Avacta Group
N/AGBX 28
-0.9%
N/A-30.9%£106.38M£26.29M-3.60120News Coverage
SLN
Silence Therapeutics
N/AN/AN/AN/A£480.35M£11.35M-11.01100High Trading Volume
PRTC
PureTech Health
1.3048 of 5 stars
GBX 129.44
+6.4%
GBX 455
+251.5%
-40.7%£388.81M£521,320.79-5.31300
OXB
Oxford Biomedica
1.3147 of 5 stars
GBX 294.90
+1.0%
GBX 560
+89.9%
-7.6%£313.48M£98.31M-2.19891
FARN
Faron Pharmaceuticals Oy
N/AGBX 228
+3.6%
N/A+4.3%£306.09MN/A-6.1034
HZD
Horizon Discovery Group plc (HZD.L)
N/AN/AN/AN/A£302.98M£54.63M-33.55416
VRP
Verona Pharma plc (VRP.L)
N/AN/AN/AN/A£228MN/A-1.6822Gap Up
ARIX
Arix Bioscience
N/AN/AN/AN/A£183.73M£14.16M1,290.919
BVXP
Bioventix
N/AGBX 2,852.50
-0.8%
N/A-33.7%£149.37M£13.65M18.4512News Coverage
4BB
4basebio
N/AGBX 1,150
+2.2%
GBX 1,600
+39.1%
-20.7%£147.32M£311,000.00-1,474.36101News Coverage
CIR
Circassia Group
N/AN/AN/AN/A£142.66M£27.90M3,400.00111Gap Down

Related Companies and Tools


This page (LON:AVCT) was last updated on 5/23/2025 by MarketBeat.com Staff
From Our Partners